Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has been given a consensus rating of “Buy” by the nine ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have […]
